Minimal Residual Disease (MRD) Testing
News and reporting on minimal residual disease testing.
Jury Awards Guardant Health $292.5M in False Advertising Lawsuit Against Natera
The companies have both claimed that the other has engaged in false advertising related to Signatera and Reveal MRD assays.
Top Five Articles on 360Dx Last Week: Tempus Buy of Ambry Genetics; Blood-Based MRD Testing; More
Last week, readers were most interested in a story about Tempus' expectations for its acquisition of cancer testing firm Ambry.
A recent survey by GenomeWeb revealed trends in the adoption and usage of various types of circulating tumor DNA assays for solid tumors.
UBS Initiates Coverage of Veracyte With Buy Rating
Analysts noted that they envision "durable growth" in Veracyte's Afirma and Decipher Prostate tests and "long-term growth potential" from its MRD testing business.
Foresight Diagnostics Founders Respond to Roche Lawsuit, Says Claims Asserted in Bad Faith
Foresight said that Roche's asserted trade secrets were not secret and that the technologies at the heart of the claim are fundamentally different.